about
Li-fraumeni syndromeFamilial breast cancer and the hCHK2 1100delC mutation: assessing cancer riskP53 functional abnormality in mesenchymal stem cells promotes osteosarcoma developmentPediatric cancer and Li-Fraumeni/Li-Fraumeni-like syndromes: a review for the pediatricianTumor suppression in skin and other tissues via cross-talk between vitamin D- and p53-signalingEndoscopic ultrasonography for surveillance of individuals at high risk for pancreatic cancerStructural Basis for ASPP2 Recognition by the Tumor Suppressor p73Activation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancerA Comprehensive Review of Pediatric Tumors and Associated Cancer Predisposition Syndromes.The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice.Identification of a novel germ-line mutation in the TP53 gene in a Mexican family with Li-Fraumeni syndrome.Genes and environment: effects on the development of second malignancies in retinoblastoma survivors.Childhood adrenocortical tumours: a review.Pancreatic cancer genomics: insights and opportunities for clinical translationRegulation of MCP-1 chemokine transcription by p53Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls.Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.A comprehensive candidate gene approach identifies genetic variation associated with osteosarcoma.Chk2 and p53 are haploinsufficient with dependent and independent functions to eliminate cells after telomere loss.In vivo analysis of p53 tumor suppressor function using genetically engineered mouse modelsClinical management of hereditary breast cancer syndromes.Translational advances regarding hereditary breast cancer syndromes.Late onset Li-Fraumeni Syndrome with bilateral breast cancer and other malignancies: case report and review of the literature.Regular surveillance for Li-Fraumeni Syndrome: advice, adherence and perceived benefits.10 rare tumors that warrant a genetics referral.Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndromep53 Family and Cellular Stress Responses in Cancer.Li-Fraumeni syndrome with simultaneous osteosarcoma and liver cancer: increased expression of a CD44 variant isoform after chemotherapyEducational paper: screening in cancer predisposition syndromes: guidelines for the general pediatrician.Molecular characteristics of endometrial cancer coexisting with peritoneal malignant mesothelioma in Li-Fraumeni-like syndrome.TP53-Associated Pediatric Malignancies.Susceptibility locus for lung cancer at 15q25.1 is not associated with risk of pancreatic cancerPEComa in a Young Patient with Known Li-Fraumeni Syndrome.Modeling familial cancer with induced pluripotent stem cellsAdrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care centerHigh-grade serous ovarian cancer arises from fallopian tube in a mouse model.Epidemiology and genetics of childhood cancer.Insulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling.Leveraging protein quaternary structure to identify oncogenic driver mutations.
P2860
Q22241780-E91C6584-F1A6-4530-8DF8-B7751FCF3332Q24803409-3B429EB0-E449-4C0C-86EB-8906665CA78BQ26771603-E3F0CBB6-5C3B-4277-9B03-3AAB7CB13A1DQ26801429-14291D8A-B6B6-4504-834C-F5C27C541474Q26992094-4C0098C7-C22A-4DA5-9E65-C9A9A62DCF8BQ27010209-1C02C912-85D3-45D7-A138-1C6FCD82F4E4Q27671671-544645EE-7371-4C86-A3FC-A954FBC9D951Q28472376-199FDDE9-4F75-4D8F-B26E-979C135FC294Q28473504-F203359D-E3FB-4483-B4A2-9640F37F3131Q30252766-BF8092D4-B471-43CD-BDE9-59251157683BQ33569721-5E9DDC97-84AE-4ABC-8233-B3EE83104C47Q33589744-0A4830CA-D31B-4559-BE79-C4C3CB9B2212Q33705736-A98C255B-4E09-481A-AC3D-6CFDCFD11191Q33722503-510B27AA-7821-4FD6-B52D-4E8645E20854Q33781071-55BC71BE-D3F6-431E-A352-314D12B8F2DCQ33828413-3D83AD09-8F0E-4382-95E9-93E4AA8A67C6Q33844055-0A5EA405-1940-4AD4-BBCE-AEC768370636Q33865095-D62DE597-E343-4CAA-ABA1-E356D58D22E2Q33914489-219FE4F9-56D9-4B86-980C-C76206ADED00Q33926851-BB5F811D-21B3-448E-9AA3-3121EECD822FQ34042319-9C764AD6-9ACC-4DCA-B631-4C2CE892E666Q34167563-C5CD841E-C9F4-46BC-984C-B11818E698E7Q34263162-8073B200-A55C-4FA5-98CF-B7582C31BC19Q34294432-85D8111A-6687-425A-A55C-AFD68E4305A1Q34306492-66527DE4-61C8-4DA4-92B1-E968F6F5597DQ34325954-7E591BE1-A57E-4C75-8AC6-2C19B2C49AD3Q34335864-DD0B6EE9-DD8A-4C26-B9AA-1C14AA8107E0Q34377287-E1CD3CC8-7DCE-4913-B781-677F4FA192B2Q34432525-D2CD74B1-B47F-454F-ACE0-8A0FA6D39F03Q34915251-26DCEBD0-1952-45F0-8516-EC82718F960BQ35033429-9B87966B-9C7B-46AC-95A8-981B7B2B6E3DQ35103165-4F672C62-E5D8-4876-8E32-7C56E43F5108Q35112899-88260D81-51CB-45B2-8A9A-74244D938B53Q35189626-592135C1-8F71-45F7-9640-A7CC65759401Q35428604-D8C3AA8A-15FA-4322-9138-89C3702064D2Q35636134-374C4119-FF84-4194-8231-20835AB82D89Q35844827-63CCDA73-72E2-49A4-8BEE-D55E1A2EC1FBQ35868038-E7972F40-095F-4229-B4BC-881A7B07C812Q35869171-D02ADAA6-2D5B-4E84-A150-04D1924509A8Q35965565-D058CA86-C236-4AB1-A9B8-67C673A666E6
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Germline TP53 mutations and Li-Fraumeni syndrome.
@ast
Germline TP53 mutations and Li-Fraumeni syndrome.
@en
Germline TP53 mutations and Li-Fraumeni syndrome.
@nl
type
label
Germline TP53 mutations and Li-Fraumeni syndrome.
@ast
Germline TP53 mutations and Li-Fraumeni syndrome.
@en
Germline TP53 mutations and Li-Fraumeni syndrome.
@nl
prefLabel
Germline TP53 mutations and Li-Fraumeni syndrome.
@ast
Germline TP53 mutations and Li-Fraumeni syndrome.
@en
Germline TP53 mutations and Li-Fraumeni syndrome.
@nl
P356
P1433
P1476
Germline TP53 mutations and Li-Fraumeni syndrome.
@en
P2093
P304
P356
10.1002/HUMU.10185
P577
2003-03-01T00:00:00Z